Session » (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1100

A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule

Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

Abstract Number: 1102

Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)

Abstract Number: 1103

Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy

Abstract Number: 1104

Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

Abstract Number: 1105

Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients

Abstract Number: 1106

Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation

Abstract Number: 1107

Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy

Abstract Number: 1108

Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

Abstract Number: 1109

Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

Abstract Number: 1110

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

Abstract Number: 1111

Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

Abstract Number: 1112

AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses

Abstract Number: 1113

Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients

Abstract Number: 1114

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout

Abstract Number: 1115

EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice

Abstract Number: 1116

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System

Abstract Number: 1117

Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

Abstract Number: 1118

The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project

Abstract Number: 1119

Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice

Abstract Number: 1120

Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients

Abstract Number: 1121

Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

Abstract Number: 1122

The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy

Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.